Growth and funding Ukko has secured substantial funding (total funding around $93M) and has growing revenue in the multi-million range, indicating readiness for partner collaborations, clinical/advisory services, and joint development opportunities with larger biopharma or agtech players focusing on allergy therapies.

Allergy immunotherapy focus The core value proposition centers on safe immunotherapies for allergies, especially peanut-related risks. This creates sales opportunities with labs, clinics, and health systems seeking innovative desensitization platforms or AI-driven protein engineering solutions to enhance safety and efficacy.

AI and protein engineering Ukko’s use of artificial intelligence and protein engineering as a differentiator opens doors for technology licensing, collaborative R&D on allergen design, and SaaS or consulting engagements around predictive modeling, optimization, and safety profiling for immune-based products.

Strategic backing Leads by Bayer’s Leaps fund and notable investors position Ukko as a credible partner for co-development, funding for joint programs, and access to broader biotech networks for early adoption pilots and regional market expansion.

Collaborative growth potential With a mid-size team and presence in AI-enabled biotech, opportunities exist for scalable service offerings, contract research, and sample-to-data partnerships with contract manufacturing organizations, CROs, and large life sciences firms aiming to accelerate allergy-related therapeutics and diagnostics.